Please login to the form below

Not currently logged in
Email:
Password:

Vivet Therapeutics

This page shows the latest Vivet Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Pfizer goes big on gene therapy with $500m facility spend

Pfizer goes big on gene therapy with $500m facility spend

That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage  haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a  ... It also took a 15% stake in  Vivet Therapeutics and its lead

Latest news

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    a 15% stake in Vivet Therapeutics earlier this year, and in-house mini-dystrophin gene therapy candidate PF-06939926 for Duchenne muscular dystrophy.

  • Catalent preps for complex therapy boom with $1.2bn Paragon buy Catalent preps for complex therapy boom with $1.2bn Paragon buy

    Last month, Pfizer paid around $640m for a 15% stake in Vivet Therapeutics, while Biogen snapped up Nightstar Therapeutics for $800m and Roche acquired Spark Therapeutics in February for $4.3bn. ... And in 2018, Novartis’ bought AveXis for $8.7bn to

  • Pfizer hedges bets on gene therapy deal Pfizer hedges bets on gene therapy deal

    Company not splashing out like Roche's Spark purchase. Pfizer has stopped short of joining 2019's gene therapy buying spree, instead acquiring a 15% of Vivet Therapeutics, and securing an ... Vivet Therapeutics’ lead candidate is VTX-801, a gene

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....

Infographics